Remedy for integration dysfunction syndrome
View Patent ↗The present invention provides a novel method for treatment of schizophrenia which can improve wide-ranging symptoms of schizophrenia, especially positive symptoms and negative symptoms without being accompanied by extrapyramidal symptoms, which comprises orally administering as an active compound (1R,2S,3R,4S)—N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or a pharmaceutically acceptable salt thereof (e.g., hydrochloride) at a daily dose of 5 mg to 120 mg once a day to a patient with schizophrenia, and a therapeutic agent to be used in the method.
1. A method for treating the negative symptoms of schizophrenia and/or the cognitive dysfunction of schizophrenia in a patient, which comprises orally administering a once daily dose of 5 mg to 120 mg of the active compound: (1R,2S,3R,4S)—N[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide of the formula (1):
or a pharmaceutically acceptable salt thereof to a patient suffering from negative symptoms of schizophrenia and/or cognitive dysfunction of schizophrenia.
2. The method of claim 1 , which is a method for treating the negative symptoms of schizophrenia in a patient.
3. The method of claim 1 , which is a method for treating the cognitive dysfunction of schizophrenia in a patient.
4. The method of claim 1 , 2 or 3 wherein the pharmaceutically acceptable salt of said active compound is (1R,2S,3R,4S)—N-[(1R,2R)-2-[4-(1,2benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride.
5. The method of any one of claims 1 , 4 , 2 and 3 , wherein a once daily dose of 20 mg to 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.
6. The method of any one of claims 1 , 4 , 2 and 3 , wherein said patient is in a chronic stage of schizophrenia, and wherein a once daily dose of 5 mg to 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.
7. The method of any one of claims 1 , 4 , 2 and 3 , wherein said patient is in an acute stage of schizophrenia, and wherein a once daily dose of 40 mg to 120 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.
8. The method of any one of claims 1 , 4 , 2 and 3 , wherein a once daily dose of 40 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.
9. The method of any one of claims 1 , 4 , 2 and 3 , wherein a once daily dose of 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.
10. The method of any one of claims 1 , 4 , 2 and 3 , wherein a once daily dose of 120 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.
11. The method of claim 6 , wherein a once daily dose of 10 mg to 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.